# Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

> **NCT00753545** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 265 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** AZD2281
- **DRUG:** matching placebo

## Key facts

- **NCT ID:** NCT00753545
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-28
- **Primary completion:** 2010-06-30
- **Final completion:** 2023-10-12
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753545, "Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00753545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*